Phase 2 randomized study of bortezomib-melphalan-prednisone with or without siltuximab (anti-IL-6) in multiple myeloma

by San-Miguel, J, Bladé, J, Shpilberg, O, Grosicki, S, Maloisel, F, Min, C.-K, Zarzuela, M.P, Robak, T, Prasad, S.V.S.S, Goh, Y.T, Laubach, J, Spencer, A, Mateos, M.-V, Palumbo, A, Puchalski, T, Reddy, M, Uhlar, C, Qin, X, Van De Velde, H, Xie, H, Orlowski, R.Z
Published 2020

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma

by Dimopoulos, M.A., Jakubowiak, A.J., McCarthy, P.L., Orlowski, R.Z., Attal, M., Bladé, J., Goldschmidt, H., Weisel, K.C., Ramasamy, K., Zweegman, S., Spencer, A., Huang, J.S.Y., Lu, J., Sunami, K., Iida, S., Chng, W.-J., Holstein, S.A., Rocci, A., Skacel, T., Labotka, R., Palumbo, A., Anderson, K.C.
Published 2021